Vaccinex (United States)

Recent papers from Vaccinex (United States)

1. Neoadjuvant pepinemab in combination with nivolumab and/or ipilimumab in resectable metastatic melanoma: a pilot biomarker-driven trialNature Communications · 2026
2. Potentiating dendritic cell immunotherapy by interrupting the Semaphorin 4D-induced immune-suppressive barrierCell Reports · 2026
3. Abstract LB-C007: Enhancing immune interactions in tumor with pepinemab SEMA4D blocking antibodyCancer Immunology Research · 2026
4. A stabilized MERS-CoV spike ferritin nanoparticle vaccine elicits robust and protective neutralizing antibody responsesNature Communications · 2026
5. Intravital imaging of the formation and resolution of MHC class II–positive T-cell activation nichesLife Science Alliance · 2025
6. Abstract A094: Myofibroblast programming blocks differentiation of immune enhancing fibroblastic reticular cells in pancreatic cancerCancer Research · 2025
7. The impact of 12C6 heavy ion irradiation-induced cellular mutations on the replication of the foot-and-mouth disease virus and the role of Cbr3Cellular and Molecular Life Sciences · 2025
8. Pepinemab: a SEMA4D antagonist for treatment of Huntington’s and other neurodegenerative diseasesExpert Opinion on Investigational Drugs · 2025
9. Advancements in Immunity and Dementia Research: Highlights from the 2023 AAIC Advancements: Immunity ConferenceAlzheimer s & Dementia · 2024
10. Abstract A004: A Phase 1B/2 trial of second line immunotherapy with pepinemab and avelumab for patients with metastatic pancreatic adenocarcinomaCancer Research · 2024
11. Correlative and spatial biomarker analysis of a phase 1/2b study to evaluate pepinemab in combination with pembrolizumab for first-line treatment of patients with recurrent or metastatic head and neck cancer.Journal of Clinical Oncology · 2024
12. A phase 1/2 study of pepinemab in children, adolescents, or young adults with recurrent or refractory solid tumors: A children's oncology group consortium report (ADVL1614)Pediatric Blood & Cancer · 2024
13. Absolute quantitation of binding antibodies from clinical samplesnpj Vaccines · 2024
14. Use of poxvirus display to select antibodies specific for complex membrane antigensmAbs · 2023
15. Conclusions of the SIGNAL study in Huntington and implications for treatment of other slowly progressive neurodegenerative diseasesClinical and Translational Medicine · 2023
16. Pepinemab antibody blockade of SEMA4D in early Huntington’s disease: a randomized, placebo-controlled, phase 2 trialNature Medicine · 2022
17. Semaphorin 4D is upregulated in neurons of diseased brains and triggers astrocyte reactivityJournal of Neuroinflammation · 2022
18. LFA-1 activation enriches tumor-specific T cells in a cold tumor model and synergizes with CTLA-4 blockadeJournal of Clinical Investigation · 2022
19. Cross-protective immunity following coronavirus vaccination and coronavirus infectionJournal of Clinical Investigation · 2021
20. Huntington’s Disease Integrated Staging System (HD-ISS): A Novel Evidence-Based Classification System For Staging2021